Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Nippon Steel & Sumitomo Metal Corporation in connection with the acquisition of Ovako
Mandate

Vinge has advised Nippon Steel & Sumitomo Metal Corporation in connection with the acquisition of Ovako

March 16, 2018 M&A

Vinge has advised Nippon Steel & Sumitomo Metal Corporation (“Nippon”) on its acquisition of Ovako from Triton. Ovako is a maker of special steel with global top level technology regarding high-cleanliness steel for bearing steel and other such products.

The acquisition of Ovako is a strategic supplement to Nippon’s business concept and will strengthen and expand Nippon’s global business and further strengthen their technology, product quality and product development capabilities for special steels and secure a base of manufacturing and sales in Europe.

Vinge’s team consisted of among others Daniel Rosvall and Ulrich Ziche as well as associates Anna Thoms, Hedvig Ekdahl, Edin Agic, Christina Odengran, Peter Issa, Johan Cederblad, Arvid Axelryd, Lisa Sennerby.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025